Stifel analyst Daniel Arias lowered the firm’s price target on Agilent to $151 from $163 and keeps a Buy rating on the shares. Agilent posted an in-line quarter, but the FY24 outlook has “come way in” as a slower recovery in biopharma along with a weaker view of China is contemplated, the analyst tells investors. Following the company’s earnings report, the firm expects shares will be down as “a fresh layer of concern gets spread across the Tools space,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- A Earnings: Agilent Tanks 13% after Issuing Weak Guidance
- Options Volatility and Implied Earnings Moves Today, May 29, 2024
- Options Volatility and Implied Earnings Moves This Week, May 28 – May 30, 2024
- Agilent Technologies (A) Q2 Earnings Cheat Sheet
- Early notable gainers among liquid option names on May 10th